Sugi Predict

Sugi Predict / Compounds / SCHEMBL901264

SCHEMBL901264

SCHEMBL901264

CC(C)(C)OC(=O)N1CCN(c2cc(Br)ccn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 8/20 0.54
▸ CKS1B P61024 2/20 0.52
▸ SKP1 P63208 2/20 0.52
▸ SKP2 Q13309 2/20 0.52
▸ LRRK2 Q5S007 1/20 0.51
▸ MAP4K4 O95819 1/20 0.50
▸ ACHE P22303 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ BACE1 P56817 2/20 0.47
▸ RET P07949 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ WNT3A P56704 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30179976 1.00 GPR119 (0.54) GPR119CKS1BSKP1SKP2LRRK2
SCHEMBL11963375 0.95 CKS1B (0.55) GPR119CKS1BSKP1SKP2LRRK2
SCHEMBL29132224 0.90 GPR119 (0.53) GPR119CKS1BSKP1SKP2LRRK2
SCHEMBL15228419 0.87 GPR119 (0.56) GPR119CKS1BSKP1SKP2LRRK2
SCHEMBL29132048 0.86 GPR119 (0.57) GPR119
SCHEMBL24671505 0.86 GPR119 (0.52) GPR119LRRK2
SCHEMBL29132280 0.86 GPR119 (0.52) GPR119CKS1BSKP1SKP2LRRK2
SCHEMBL30066214 0.86 GPR119 (0.52) GPR119LRRK2
SCHEMBL113805 0.86 GPR119 (0.55) GPR119CKS1BSKP1SKP2LRRK2
SCHEMBL29132285 0.85 GPR119 (0.55) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 — — EP disclosed
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-17 — — US disclosed
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-06-05 — — US disclosed
US-20250179059-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-06-05 — — US disclosed
US-12162870-B2 Anticancer compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 — — US disclosed
EP-4351560-A1 ANTICANCER COMPOUNDS The Regents of the University of California (US) 2024-04-17 — — EP disclosed
CN-117794525-A Anticancer compounds 加利福尼亚大学董事会 2024-03-29 — — CN disclosed
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-01-02 — — US disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 — — US disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 — — US disclosed
EP-2489663-A1 Compounds as syk kinase inhibitors Almirall, S.A. (ES) 2012-08-22 — — EP disclosed
EP-2441755-A1 Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors Almirall, S.A. (ES) 2012-04-18 — — EP disclosed
EP-2441755-A1 Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors Almirall, S.A. (ES) 2012-04-18 — — EP disclosed
WO-2012041476-A1 PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS ALMIRALL, S.A. (ES) 2012-04-05 — — WO disclosed
WO-2012041476-A1 PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS ALMIRALL, S.A. (ES) 2012-04-05 — — WO disclosed
EP-2300430-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-Tech Ueno, Ltd. (JP) 2011-03-30 — — EP disclosed
US-20110059957-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-TECH UENO, LTD. (JP) 2011-03-10 — — US disclosed
US-20110059957-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-TECH UENO, LTD. (JP) 2011-03-10 — — US disclosed
US-20110059957-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-TECH UENO, LTD. (JP) 2011-03-10 — — US disclosed
WO-2009145360-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-TECH UENO, LTD. (JP) 2009-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179059-A1 ANTICANCER COMPOUNDS BET1, BRD4, BICRA GPR119 2737/4885CKS1B 294/4885SKP1 1116/4885
US-20110059957-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR VAPB, VAPA, BET1 GPR119 3327/4885CKS1B 4194/4885SKP1 452/4885
US-20230348452-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, BRCA1 GPR119 2662/4885CKS1B 1343/4885SKP1 4544/4885
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use LRRK2, ADRM1, CRBN GPR119 2781/4885CKS1B 155/4885SKP1 1588/4885
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NQO1, VHL, SDHA GPR119 3532/4885CKS1B 1697/4885SKP1 1099/4885
US-12162870-B2 Anticancer compounds BET1, BRD4, BICRA GPR119 2737/4885CKS1B 294/4885SKP1 1116/4885
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 GPR119 4141/4885CKS1B 380/4885SKP1 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.